Search results

| group2 = [[Receptor antagonist|Receptor antagonist]]s and/or [[Reuptake inhibitor|reuptake inhibitor]]s ...| group1 = <small>[[Serotonin antagonist and reuptake inhibitor|Serotonin antagonists and reuptake inhibitor]]s (SARIs)</small>

| group2 = [[CB1 receptor|CB₁]] [[Agonist]]s ([[Cannabinoid]]s) | group5 = [[Muscarinic acetylcholine receptor|mACh]] [[Receptor_Antagonist|Antagonist]]s ([[Anticholinergic]]s)

...ergic agonist|AA]]'' ([[Clonidine]]){{·}} ''[[Cannabinoid receptor type 1|CB1]]'' ([[Surinabant]]) ...or|mGluR]]'' ([[Acamprosate]]){{·}} ''[[opioid antagonist|Opioid receptor antagonists]]'' ([[Naltrexone]], [[Nalmefene]]){{·}} [[Topiramate]]{{·}} ''[[Adrenerg

...ervous]] and [[immune system]]s of animals and that activate [[cannabinoid receptor]]s , and 3. '''synthetic cannabinoids''', a structurally diverse class of m {{Main|Cannabinoid receptor}}

...51.</ref>. It is widely used for screening drugs that induce [[cannabinoid receptor]]-mediated effects in rodents. The four behavioral components of the tetrad ...tment with [[Receptor antagonist|antagonist]]s of [[Cannabinoid receptor 1|CB1]] such as [[rimonabant]].

...|CB₁]] receptor, which is the most abundant [[G protein-coupled receptor]] in the [[brain]]. ...tor]] antagonist [[rimonabant]] (SR141716A) as well as [[opioid receptor]] antagonists (opioid blockers) [[naloxone]] and [[naloxonazine]].<ref name="Lupica 2004"

...ions of marijuana smokers <ref name=Gruber2009/>. The central cannabinoid (CB1) receptors in the basal ganglia, the [[cerebral cortex]] and the [[cerebell ..., that are able to block the activation of the cannabinoid receptor. These antagonists could serve as a contemporary means for treating drug addiction since they